

# Ligand Design in Medicinal Inorganic Chemistry

Edited by

**TIM STORR**

Department of Chemistry, Simon Fraser University, Burnaby, BC V5A-1S6, Canada

**WILEY**

# Contents

<i>About the Editor</i>	<i>xiii</i>
<i>List of Contributors</i>	<i>xv</i>
<b>1 Introduction to Ligand Design in Medicinal Inorganic Chemistry</b>	<b>1</b>
<i>Michael R. Jones, Dustin Duncan, and Tim Storr</i>	
References	7
<b>2 Platinum-Based Anticancer Agents</b>	<b>9</b>
<i>Alice V. Klein and Trevor W. Hambley</i>	
2.1 Introduction	9
2.2 The advent of platinum-based anticancer agents	9
2.3 Strategies for overcoming the limitations of cisplatin	11
2.4 The influence of ligands on the physicochemical properties of platinum anticancer complexes	11
2.4.1 Lipophilicity	11
2.4.2 Reactivity	13
2.4.3 Rate of reduction	14
2.5 Ligands for enhancing the anticancer activity of platinum complexes	15
2.5.1 Ligands for improving DNA affinity	15
2.5.2 Ligands for inhibiting enzymes	17
2.6 Ligands for enhancing the tumour selectivity of platinum complexes	20
2.6.1 Ligands for targeting transporters	21
2.6.2 Ligands for targeting receptors	22
2.6.3 Ligands for targeting the EPR effect	28
2.6.4 Ligands for targeting bone cancer	33
2.7 Ligands for photoactivatable platinum complexes	35
2.8 Conclusions	36
References	37
<b>3 Coordination Chemistry and Ligand Design in the Development of Metal Based Radiopharmaceuticals</b>	<b>47</b>
<i>Eszter Boros, Bernadette V. Marquez, Oluwatayo F. Ikotun, Suzanne E. Lapi, and Caru L. Ferreira</i>	
3.1 Introduction	47
3.1.1 Metals in nuclear medicine	48
3.1.2 The importance of coordination chemistry	49
3.1.3 Overview	50

3.2	General metal based radiopharmaceutical design	50
3.2.1	Choice of radionuclide	50
3.2.2	Production of the radiometal starting materials	51
3.2.3	Ligand and chelate design consideration	51
3.3	Survey of the coordination chemistry of radiometals applicable to nuclear medicine	53
3.3.1	Technetium	53
3.3.2	Rhenium	56
3.3.3	Gallium	57
3.3.4	Indium	60
3.3.5	Yttrium and lanthanides	61
3.3.6	Copper	62
3.3.7	Zirconium	65
3.3.8	Scandium	66
3.3.9	Cobalt	68
3.4	Conclusions	71
	References	71
<b>4</b>	<b>Ligand Design in <i>d</i>-Block Optical Imaging Agents and Sensors</b>	<b>81</b>
	<i>Mike Coogan</i>	
4.1	Summary and scope	81
4.2	Introduction	82
4.2.1	Criteria for biological imaging optical probes	82
4.3	Overview of transition-metal optical probes in biomedical applications	83
4.3.1	Common families of transition metal probes	83
4.4	Ligand design for controlling photophysics	87
4.4.1	Photophysical processes in transition metal optical imaging agents and sensors	87
4.4.2	Photophysically active ligand families – tuning electronic levels	87
4.4.3	Ligands which control photophysics through indirect effects	90
4.4.4	Transition metal optical probes with carbonyl ligands	90
4.5	Ligand design for controlling stability	91
4.6	Ligand design for controlling transport and localisation	91
4.6.1	Passive diffusion	91
4.6.2	Active transport	92
4.7	Ligand design for controlling distribution	92
4.7.1	Mitochondrial-targeting probes	92
4.7.2	Nuclear-targeting probes	93
4.7.3	Bioconjugation	94
4.8	Selected examples of ligand design for important individual probes	101
4.8.1	A pH-sensitive ligand to control Ir luminescence	101
4.8.2	Dimeric NHC ligands for gold cyclophanes	102
4.9	Transition metal probes incorporating or capable of more than one imaging mode	103
4.9.1	Bimodal MRI/optical probes	103
4.9.2	Bimodal radio/optical probes	104
4.9.3	Bimodal IR/optical probes	106
4.10	Conclusions and prospects	106
	Abbreviations	108
	References	108

<b>5</b>	<b>Luminescent Lanthanoid Probes</b>	<b>113</b>
	<i>Edward S. O'Neill and Elizabeth J. New</i>	
5.1	Introduction	113
5.2	Luminescent probes	114
5.3	The lanthanoids – an overview	116
5.4	Photophysical properties of luminescent lanthanoid complexes	116
5.4.1	The need for a sensitiser	117
5.5	The suitability of lanthanoid complexes as luminescent probes	119
5.6	Modulating chemical properties by ligand design	120
5.6.1	Chemical stability	120
5.6.2	Photophysical properties	122
5.6.3	Analyte response	123
5.7	Modulating biological properties by ligand design	129
5.7.1	Cellular uptake	129
5.7.2	Localisation to desired region of the cell	131
5.7.3	Maintenance of cellular homeostasis	135
5.8	Concluding remarks	138
	Acknowledgement	138
	References	138
<b>6</b>	<b>Metal Complexes of Carbohydrate-targeted Ligands in Medicinal Inorganic Chemistry</b>	<b>145</b>
	<i>Yuji Mikata and Michael Gottschaldt</i>	
6.1	Introduction	145
6.2	Radioactive metal complexes bearing a carbohydrate moiety	147
6.3	MRI contrast agents utilizing metal complexes bearing carbohydrate moieties	150
6.4	Fluorescent complexes with carbohydrate-conjugated functions	153
6.5	Carbohydrate-attached photosensitizers for photodynamic therapy (PDT)	157
6.6	Carbohydrate-based metal complexes exhibiting anticancer activity	161
6.7	Carbohydrate-appended metallic nanoparticles, quantum dots, electrodes and surfaces	165
6.8	Concluding remarks	167
	References	168
<b>7</b>	<b>Design of Schiff Base-derived Ligands: Applications in Therapeutics and Medical Diagnosis</b>	<b>175</b>
	<i>Rafael Pinto Vieira and Heloisa Beraldo</i>	
7.1	Introduction	175
7.2	Design of thiosemicarbazones and hydrazones as drug candidates for cancer chemotherapy	176
7.3	Design of bis(thiosemicarbazone) ligands	184
7.3.1	Bis(thiosemicarbazones) and their metal complexes as anticancer agents	184
7.3.2	Design of bis(thiosemicarbazones) as ligands for copper(II) complexes with potential applications in medical diagnosis	186
7.3.3	Design of functionalized bis(thiosemicarbazone) ligands to target selected biological processes	189
7.4	Design of Schiff base-derived ligands as anti-parasitic drug candidates: Applications in the therapeutics of chagas disease	193

7.5	Concluding remarks	197
	References	197
<b>8</b>	<b>Metal-based Antimalarial Agents</b>	<b>205</b>
	<i>Maribel Navarro and Christophe Biot</i>	
8.1	Background	205
8.2	Standard antimalarial chemotherapy	208
	8.2.1 Quinoline-based antimalarials	208
	8.2.2 Quinoline-based antimalarials target	209
	8.2.3 Other standard antimalarial therapies	210
8.3	Metal complexes in malaria	212
	8.3.1 Chloroquine as an inter-ligand in the design of metal-based antimalarial agents	212
	8.3.2 Chloroquine as an intra-ligand in the design of metal-based antimalarial agents	214
	8.3.3 Trioxaquinones as a ligand in the design of metal-based antimalarial agents	218
	8.3.4 Other standard antimalarial drugs and diverse ligands used in the design of metal-based antimalarial agents	218
8.4	Conclusion	220
	Acknowledgements	221
	References	221
<b>9</b>	<b>Therapeutic Gold Compounds</b>	<b>227</b>
	<i>Susan J. Berners-Price and Peter J. Barnard</i>	
9.1	Introduction	227
9.2	Antiarthritic gold drugs	229
	9.2.1 Gold (I) thiolates	229
	9.2.2 Gold (I) phosphines	229
	9.2.3 Design of specific enzyme inhibitors	230
9.3	Gold complexes as anticancer agents	231
	9.3.1 Gold(I) compounds	231
	9.3.2 Gold (III) compounds	241
9.4	Gold complexes as antiparasitic agents	244
	9.4.1 Metal drug synergism	245
	9.4.2 Emerging parasite drug targets for gold compounds	245
9.5	Concluding remarks: Design of gold complexes that target specific proteins	246
	Acknowledgements	248
	References	248
<b>10</b>	<b>Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases</b>	<b>257</b>
	<i>Michael W. Beck, Amit S. Pithadia, Alaina S. DeToma, Kyle J. Korshavn, and Mi Hee Lim</i>	
10.1	Introduction	257
	10.1.1 Metals in the brain	257
	10.1.2 Aberrant metal–protein interactions	259
	10.1.3 Oxidative stress	260
10.2	Neurodegenerative diseases	261
	10.2.1 Alzheimer’s disease (AD)	261
	10.2.2 Parkinson’s disease (PD)	261

10.2.3	Prion disease	261
10.2.4	Huntington's disease (HD)	264
10.2.5	Amyotrophic lateral sclerosis (ALS)	264
10.3	Ligand design to target and modulate metal–protein interactions	265
10.3.1	Metal chelating compounds	267
10.3.2	Small molecules designed for metal–protein complexes	269
10.3.3	Other relevant compounds	272
10.3.4	Naturally occurring molecules	273
10.4	Conclusions	274
	Abbreviations	275
	References	276
<b>11</b>	<b>Rational Design of Copper and Iron Chelators to Treat Wilson's Disease and Hemochromatosis</b>	<b>287</b>
	<i>Christelle Gateau, Elisabeth Mintz, and Pascale Delangle</i>	
11.1	Introduction	287
11.2	Chelating agents	288
11.2.1	Thermodynamic parameters	288
11.2.2	Principles of coordination chemistry applied to chelation therapy	289
11.2.3	Examples of classical chelating agents	290
11.3	Modern medicinal inorganic chemistry and chelation therapy	291
11.4	Iron overload	292
11.4.1	Iron distribution and homeostasis	292
11.4.2	Iron overload diseases	294
11.4.3	Fe <sup>3+</sup> chelators	295
11.4.4	Current developments	296
11.5	Copper overload in Wilson's disease	299
11.5.1	Copper metabolism	299
11.5.2	Copper homeostasis	300
11.5.3	Wilson's disease	303
11.6	Current developments in copper overload treatments	304
11.6.1	From Cu homeostasis understanding to the rational design of drugs	304
11.6.2	Cu <sup>+</sup> chelating units inspired from proteins involved in Cu homeostasis	305
11.6.3	Cu <sup>+</sup> chelators inspired from metallochaperones	306
11.6.4	Cysteine-rich compounds inspired from metallothioneins	307
11.6.5	Liver-targeting: the ASGP-R	308
11.6.6	Two glycoconjugates that release high affinity Cu chelators in hepatocytes	308
11.7	Conclusion	311
	Acknowledgments	312
	References	312
<b>12</b>	<b>MRI Contrast Agents</b>	<b>321</b>
	<i>Célia S. Bonnet and Éva Tóth</i>	
12.1	Introduction to MRI contrast agents	321
12.2	Ligand optimization to increase relaxivity	323
12.2.1	Hydration number	324
12.2.2	Optimization of water exchange kinetics via rational ligand design	325

12.2.3	Optimization of the rotational dynamics via rational ligand design: Size and flexibility	329
12.3	Ligand design for CEST agents	332
12.3.1	Application of paramagnetic ions – PARACEST	333
12.4	Ligand design for responsive probes	333
12.4.1	Probes responsive to pH	334
12.4.2	Probes responsive to physiological cations	338
12.4.3	Probes responsive to enzymes	344
12.5	Conclusions	348
	Abbreviations	348
	References	348
<b>13</b>	<b>Photoactivatable Metal Complexes and Their Use in Biology and Medicine</b>	<b>355</b>
	<i>Tara R. deBoer-Maggard and Pradip K. Mascharak</i>	
13.1	Introduction	355
13.2	Cisplatin-inspired photoactivatable chemotherapeutics	358
13.3	Metal-based photosensitizers in photodynamic therapy	360
13.4	Photoinduced interactions of coordination complexes with DNA	362
13.4.1	Photocleavage of DNA with coordination complexes	362
13.4.2	Photoactivatable complexes as antisense agents	364
13.5	Photoactivatable metal complexes that release small bioactive molecules	367
13.6	Conclusion	371
	References	372
<b>14</b>	<b>Metalloprotein Inhibitors</b>	<b>375</b>
	<i>David P. Martin, David T. Puerta, and Seth M. Cohen</i>	
14.1	Metal binding groups in metalloprotein inhibitor design	375
14.2	Thiols, carboxylates, phosphates, and hydroxamates	379
14.3	MBGs related to hydroxamic acids	382
14.4	MBGs related to carboxylic acids	387
14.5	MBGs related to thiols	391
14.6	Amine, alcohol, and carbonyl MBGs	393
14.7	Other MBGs	395
14.8	Conclusion	399
	References	401
<b>15</b>	<b>Ruthenium Anticancer Compounds with Biologically-derived Ligands</b>	<b>405</b>
	<i>Changhua Mu and Charles J. Walsby</i>	
15.1	Introduction	405
15.1.1	Simple coordination complexes	406
15.1.2	Ruthenium(III) complexes with heterocyclic N-donor and/or DMSO ligands	406
15.1.3	Ruthenium(II) arene complexes	408
15.1.4	Polypyridyl complexes	410
15.1.5	Other ruthenium anticancer compounds	411
15.2	Amino acids and amino acid-containing ligands	411
15.3	Peptides and peptide-functionalized ligands	413
15.4	Coordinated proteins as ligands	416

15.5	Carbohydrate-based ligands	419
15.6	Purine, nucleoside, and oligonucleotide ligands	422
15.7	Other selected ruthenium complexes with biological ligands	424
	15.7.1 steroids	424
	15.7.2 Curcumin – an example of a natural product ligand	425
15.8	Conclusion	426
	References	426
	<b>Index</b>	<b>439</b>